APP and Alzheimer disease: A preclinical finding illustrated that triple receptor agonists of GLP-1, GIP, and the glucagon receptor attenuate AD neuropathology in transgenic mice with mutant APP by reducing the formation of Aβ (Tai et al. 2018).